Table 1.
Characteristics of matched cases and controls for the full population in the skin, lip and oral cavity cancer case control analyses
| SCC | BCC | Melanoma | Lip cancer | Oral cavity cancer | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls | |
| Number of individuals | 7560 | 151 194 | 89 088 | 1 781 712 | 11 185 | 223 700 | 707 | 70 500 | 3516 | 70 328 |
| Female sex, n (%) | 3015 (40.0) | 60 300 (40.0) | 43 507 (48.8) | 870 140 (48.8) | 6365 (56.9) | 127 300 (56.9) | 239 (33.8) | 23 700 (33.6) | 1175 (33.4) | 23 500 (33.4) |
| Age (y), mean ± SD | 74.8 (11.5) | 74.8 (11.5) | 68.3 (13.6) | 68.3 (13.6) | 58.2 (16.4) | 58.2 (16.4) | 63.8 (13.6) | 63.8 (13.6) | 61.5 (13.2) | 61.5 (13.2) |
| Years of follow‐up, mean ± SD* | 9.3 (4.4) | 9.3 (4.4) | 7.2 (4.6) | 7.2 (4.6) | 7.1 (4.6) | 7.1 (4.6) | 6.2 (4.2) | 6.2 (4.2) | 7.3 (4.5) | 7.3 (4.5) |
| Body mass index (kg/m2), mean ± SD | 28.0 (5.4) | 28.5 (5.5) | 27.6 (5.4) | 28.1 (5.7) | 27.9 (5.8) | 28.0 (6.0) | 27.1 (6.1) | 28.9 (5.7) | 27.3 (5.9) | 28.3 (5.7) |
| Missing body mass index, n (%) | 636 (8.4) | 46 329 (30.6) | 10 812 (12.1) | 545 587 (30.6) | 1581 (14.1) | 66 370 (29.7) | 136 (19.2) | 21 739 (30.8) | 527 (15.0) | 20 334 (28.9) |
| Charlson comorbidity index ≥1, n (%) | 4133 (54.7) | 64 305 (42.5) | 37 125 (41.7) | 665 808 (37.4) | 3466 (31.0) | 62 846 (28.1) | 316 (44.7) | 22 889 (32.5) | 1483 (42.2) | 21 112 (30.0) |
| Current smokers, n (%) | 910 (12.0) | 14 041 (9.3) | 9825 (11.0) | 205 521 (11.5) | 1349 (11.0) | 31 614 (11.5) | 258 (40.8) | 9755 (18.8) | 1130 (40.9) | 10 355 (19.3) |
| Missing smoking status, n (%) | 180 (2.4) | 38 989 (25.7) | 6581 (7.4) | 468 070 (26.3) | 877 (7.8) | 55 811 (25.0) | 75 (10.6) | 18 633 (26.4) | 260 (7.4) | 19 625 (26.8) |
| Prior alcohol abuse, n (%) | 87 (1.2) | 1396 (0.9) | 782 (0.9) | 17 182 (1.0) | 69 (0.6) | 2262 (1.0) | 62 (8.8) | 910 (1.3) | 412 (11.7) | 966 (1.4) |
| Retinoid therapy, n (%) | 11 (0.2) | 92 (0.1) | 158 (0.2) | 1638 (0.1) | 44 (0.4) | 456 (0.2) | 1 (0.1) | 83 (0.1) | 6 (0.2) | 80 (0.1) |
| Tetracycline therapy, n (%) | 913 (12.1) | 11 896 (7.9) | 8872 (10.0) | 128 530 (7.2) | 1019 (9.1) | 16 866 (7.5) | 56 (7.9) | 4453 (6.2) | 311 (8.9) | 4805 (6.8) |
| Macrolide therapy, n (%) | 1314 (17.4) | 17 995 (11.9) | 12 012 (13.5) | 181 214 (10.2) | 1382 (12.4) | 23 449 (10.5) | 88 (12.5) | 6118 (8.7) | 424 (12.1) | 6838 (9.7) |
| Amiodarone therapy, n (%) | 125 (1.7) | 1796 (1.2) | 1067 (1.2) | 14 505 (0.8) | 77 (0.7) | 1049 (0.5) | 7 (1.0) | 478 (0.7) | 26 (0.7) | 375 (0.5) |
| Quinolone therapy, n (%) | 522 (6.9) | 6869 (5.4) | 4315 (4.8) | 59 731 (3.4) | 362 (3.2) | 6411 (2.9) | 28 (4.0) | 1885 (2.7) | 130 (3.7) | 2054 (2.9) |
| Aspirin therapy, n (%) | 2616 (34.6) | 39 420 (26.1) | 21 171 (23.8) | 327 345 (18.4) | 1546 (13.8) | 26 265 (11.7) | 152 (21.5) | 10 819 (15.4) | 650 (18.5) | 9513 (13.5) |
| NSAID therapy, n (%) | 4003 (53.0) | 58 446 (38.7) | 39 502 (44.3) | 611 882 (34.3) | 4002 (35.8) | 69 137 (30.9) | 277 (39.2) | 21 732 (30.8) | 1403 (39.2) | 22 815 (32.4) |
| Statin therapya, n (%) | 2885 (38.2) | 43 374 (28.7) | 21 831 (24.5) | 337 951 (19.0) | 1854 (16.6) | 30 861 (13.8) | 143 (20.2) | 11 611 (16.5) | 743 (21.1) | 12 098 (17.2) |
| Hydrochlorothiazide therapy, n (%) | 140 (1.9) | 1881 (1.2) | 958 (1.1) | 15 554 (0.9) | 86 (0.8) | 1407 (0.6) | 8 (1.1) | 453 (0.6) | 26 (0.7) | 518 (0.7) |
| Prior nonmelanoma skin cancer, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 30 (4.2) | 1006 (1.4) | 1 (0.0) | 950 (1.4) |
SD = standard deviation; NSAID = nonsteroidal anti‐inflammatory drug.
*
Years of follow‐up = this is the observed mean follow‐up measured from cohort entry to the index date.